BARCLAYS PLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 51 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
BARCLAYS PLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2020$1,950,000
+1641.1%
2,629,000
+1805.1%
0.00%
Q1 2020$112,000
-86.1%
138,000
-85.3%
0.00%
-100.0%
Q3 2019$805,000
+509.8%
936,000
+532.4%
0.00%
Q2 2019$132,000
+2100.0%
148,000
+2014.3%
0.00%
Q4 2018$6,000
-97.3%
7,000
-97.6%
0.00%
Q3 2017$226,000293,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2019
NameSharesValueWeighting ↓
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$56,098,0001.12%
L & S Advisors Inc 795,000$767,0000.14%
OAKTREE CAPITAL MANAGEMENT LP 9,964,000$9,690,0000.11%
WEDBUSH SECURITIES INC 13,000$1,251,0000.07%
Kohlberg Kravis Roberts & Co. L.P. 3,163,000$3,076,0000.06%
ZAZOVE ASSOCIATES LLC 246,000$240,0000.02%
Balboa Wealth Partners 21,000$200.01%
Russell Investments Group, Ltd. 1,910,000$1,875,0000.00%
GAMCO INVESTORS, INC. ET AL 250,000$244,0000.00%
Regal Investment Advisors LLC 20,000$19,0000.00%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders